Posted by Michael Wonder on 19 Apr 2018
Industry fears disruption as EU excludes UK from drug approvals
18 April 2018 - A European decision to exclude Britain from the EU’s drug approval system from March 30 2019 - the day after Brexit - has raised alarm among drug makers, who fear the abrupt change could disrupt medicine supplies to patients.
The move confounds hopes for continued joint cooperation via the European Medicines Agency (EMA), at least during a transition or implementation period until the end of 2020 when the UK will remain closely tied to the European Union.
Prime Minister Theresa May said in a speech on March 2 that London wanted to explore ways to keep Britain a part of EU agencies, such as the EMA.
